Wall Street Zen Upgrades Keros Therapeutics (NASDAQ:KROS) to “Sell”

Keros Therapeutics (NASDAQ:KROS) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Several other equities analysts also recently issued reports on KROS. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday, August 4th. Leerink Partners dropped their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Stock Up 8.3%

NASDAQ:KROS opened at $11.68 on Monday. The stock has a market capitalization of $231.61 million, a price-to-earnings ratio of -3.16 and a beta of 0.99. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55. The firm has a 50 day moving average of $10.75 and a 200 day moving average of $11.70.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, analysts expect that Keros Therapeutics will post -5.27 EPS for the current year.

Insider Transactions at Keros Therapeutics

In related news, Director Nima Farzan sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director owned 9,767 shares in the company, valued at approximately $104,799.91. This represents a 21.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total transaction of $28,140.00. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at $104,702.24. This represents a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,768 shares of company stock worth $144,979 in the last ninety days. Corporate insiders own 12.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. California State Teachers Retirement System boosted its stake in shares of Keros Therapeutics by 72.6% in the second quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock worth $29,000 after buying an additional 1,148 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the period. Tower Research Capital LLC TRC raised its position in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares in the last quarter. Legal & General Group Plc acquired a new position in Keros Therapeutics in the second quarter valued at approximately $90,000. Finally, PDT Partners LLC purchased a new stake in Keros Therapeutics in the 2nd quarter worth approximately $122,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.